Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years

Cancer

Volumn 123, Issue 4, 2017, Pages 592-599

  Pinsky, Paul F ^a   Prorok, Philip C ^a   Yu, Kelly ^a   Kramer, Barnett S ^a   Black, Amanda ^a   Gohagan, John K ^b   Crawford, E David ^c   Grubb, Robert L ^d   Andriole, Gerald L ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

digital rectal examination (DRE); prostate cancer; prostate specific antigen (PSA); randomized trial; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALL CAUSE MORTALITY; ANTIGEN DETECTION; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HUMAN; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; BLOOD; EARLY CANCER DIAGNOSIS; MIDDLE AGED; NON PROFIT ORGANIZATION; PATHOLOGY; PROSTATE TUMOR;

AGED; AMERICAN CANCER SOCIETY; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 85006317950     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30474     Document Type: Article

References (16)

1. Surveillance, Epidemiology, and End Results Program. SEER cancer statistics review (CSR) 1975-2013. http://seer.cancer.gov/csr/1975_2013/. Accessed July 5, 2016.
2. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:762–771.
3. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer. U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120–134.
4. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–2035.
5. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981–990.
6. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:1–8.
7. Andriole GL, Grubb RL, Buys SS et al. Mortality results from a randomized prostate cancer screening trial. N Engl J Med. 2009;360:1310–1319.
8. Miller AB, Feld R, Fontana R, et al. Changes in and impact of the death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Rev Recent Clin Trials. 2015;10:206–211.
9. Black A, Huang W, Wright P, et al. PLCO: evolution of an epidemiologic resource and opportunities for future studies. Rev Recent Clin Trials. 2015;10:238–245.
10. Murphy SA, Van Der Vaart AW. On profile likelihood. J Am Stat Assoc. 2000;95:449–465.
11. Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34:187–220.
12. Prorok PC, Andriole GL, Bresalier R, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21:273S–309S.
13. Pinsky, PF, Black A, Kramer BS, et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010;7:303–311.
14. Shoag J, Mittal S, Hu JC. Reevaluating PSA testing rates in the PLCO trial. N Engl J Med. 2016;374:1795–1796.
15. Pinsky P, Prorok P. Re: Reevaluating PSA testing rates in the PLCO trial. N Engl J Med. 2016;375:1500.
16. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–1424.